


Update by EMCDDA

Think Tank on HIV/AIDS, Luxembourg, 4-5 December 2012 Session: HIV in key populations – Migrants and Injecting Drug Users




European Monitoring Centre for Drugs and Drug Addiction

Annual report package 2012



Annual report



Statistical bulletin



Selected issues

- Prisons and drugs in Europe
- Pregnancy, childcare and the family



Country overviews

Drugnet Europe

Other publications

- Summary of the 2011 ESPAD report
- Trendspotter summary: fentanyl report
- Prevalence of daily cannabis use
- EMCDDA-Europol Joint report: 4-methylamphetamine
- Update on HIV outbreaks in Greece and Romania

Opioid use

About 1.4 million regular opioid users 4 per 1000 adults in the EU



Overall stable, heroin declining Long term trends:

- Ageing cohort,
- Decline in new treatment entrants,
- Less injecting,
- Increasing treatment coverage.

2010-2011 heroin shortages led to replacements: synthetic opioids, but also stimulants (cathinones)



HIV/HCV among PWIDs

Notifications of HIV infections among PWIDs low, outbreaks documented in EL and RO since 2011.



Latest (2011) ECDC surveillance data document increase in number of PWIDs: 5.4% of new cases in the EU/EEA.

- HIV rates among young injectors (< 25 yrs) exceed 5% in EE, FR, LV,
 LT, PL and are increasing since 2005 in Sofia;
- HCV antibody levels in sub-national studies range from 14%-70% and exceed 40% in 7 national samples; HCV prevalence among new injectors (< 2 yrs) in EL rising;
- HCV prevalence indicates injecting risk behaviours sufficient for HIV transmission.


Increasing treatment provision




At least 1.1 million Europeans undergo drug treatment every year (all drugs)

710 000 opioid substitution treatments in 2010

Estimated 50 % coverage rate for opioid substitution treatment in the EU



OST coverage among the estimated opioid use populations



*or most recent year available www.emcdda.europa.eu



Selected Issue: Prisons and drugs in Europe



635 000 in EU prisons on a given day (1.9.2010)

High levels of drug use (before and within prison)

High overdose risk after prison release

10 to 25 % incarcerated for drug law offences

Prisons — responses



Setting for contact with 'hard-to-reach' problem drug users

Gradual adoption of substitution treatment

Need to improve equivalence of care

Prison health services for 40% of Europe's prisoners under Health Ministries.



Prisons— implementing substitution treatment




Cumulative number of EU countries with opioid substitution treatment in community and prison settings






Proportion of prison population in opioid substitution treatment on a given day



Detecting new drugs

New substances reported to the European early warning system — 1 a week

Synthetic cathinones and cannabinoids most common



12 October 2012 in Lisbon:2nd meeting "Detecting and responding to outbreaks of HIV among PWIDs"

jointly organised by EMCDDA and ECDC

Countries attending:

AT, BG, EE, EL, HU, IT, LV, LT and RO.

Meeting report in preparation.

European guidance on prevention of infections among people who inject trugs

Comprehensive Guidance document

Based on evidence and fully referenced (50 pages)

Guidance "in brief"

Condensed recommendations (8 pages)

Two part evidence assessment

Needle and syringe programmes and other interventions for preventing hepatitis C, HIV and injecting risk behaviour (144 pages)

Drug treatment for preventing hepatitis C, HIV and injecting risk behaviour (62 pages)



Available at: www.emcdda.europa.eu

www.emcdda.europa.eu

Thank you!

• www.emcdda.europa.eu